Microbiome Research and Development: An Open Letter From Karin Loser
Posted 3rd March 2017 by Jane Williams
The skin acts as an interface between the body and the external environment, protecting us from infections or toxins. It is also home to various microbial communities. The balance of commensal bacteria is indicative of healthy skin, with dysbiosis having been linked to various skin diseases, such as psoriasis. A high relative abundance of Actinobacteria has been detected in healthy human skin but inflammatory lesions from psoriasis patients are characterised by an over-representation of Proteobacteria and an under-representation of Actinobacteria.
It’s a pleasure to be speaking at the upcoming Microbiome R&D and Business Collaboration Forum: Europe, enabling me to inform you about the implications of these findings in the treatment of psoriasis, our speculation and subsequent investigation. I’m looking forward to discussing this in more detail at the event.
I’m also looking forward to the panel discussion on day one, which will be focused on research into the skin microbiome: the developments, challenges and translational aspects. Whilst skin microbiome research is a relatively new area, companies are already translating their work into viable products. With the potential to really impact healthcare and people’s lives, these are exciting times.
I hope that you will be able to join the meeting in Amsterdam to review the developments across the vast field of microbiome research.
Professor, Department of Dermatology, Experimental Dermatology and Immunobiology of the Skin, University of Münster, Germany
Considering attending? Get a taste of what’s to come; take a look at the summary of last year’s talks.